ReviewAdvances in anatomic pathology2012
New therapeutic targets in soft tissue sarcoma.
Review in Advances in anatomic pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP): unravelling the tumor's genetic landscape.EXCLI journal · 2024Review
- Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing.Cancers · 2020Article
- Immunotherapy with nivolumab for the treatment of soft tissue sarcoma with pulmonary metastasis: A case report.Molecular and clinical oncology · 2020Article
- Neoadjuvant Treatment Options in Soft Tissue Sarcomas.Cancers · 2020Review
- Calcium-Dependent Calpain Activation-Mediated Mitochondrial Dysfunction and Oxidative Stress Are Required for Cytotoxicity of Epinecidin-1 in Human Synovial Sarcoma SW982 Cells.International journal of molecular sciences · 2020Article
- The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas.Oncotarget · 2020Article
- Prognostic Value of a Three-DNA Methylation Biomarker in Patients with Soft Tissue Sarcoma.Journal of oncology · 2020Article
- Gene amplification and tumor grading in parosteal osteosarcoma.Journal of the Chinese Medical Association : JCMA · 2019Article
- Elucidating the transcriptional program of feline injection-site sarcoma using a cross-species mRNA-sequencing approach.BMC cancer · 2019Article
- Bcl-xScientific reports · 2019Article
- Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets.BMC medical genetics · 2018Article
- Managing sarcoma: where have we come from and where are we going?Therapeutic advances in medical oncology · 2017Review
- Telomere maintenance in soft tissue sarcomas.Journal of clinical pathology · 2017Review
- The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness.PLoS genetics · 2017Article
- Article
- Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma.JAMA surgery · 2016Article
- Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.Cancer letters · 2016Review
- The importance of Src signaling in sarcoma.Oncology letters · 2015Article
- Combining targeted agents with modern radiotherapy in soft tissue sarcomas.Journal of the National Cancer Institute · 2014Review
- Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.Annals of surgical oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Soft tissue sarcomas are an uncommon and diverse group of more than 50 mesenchymal malignancies. The pathogenesis of many of these is poorly understood, but others have begun to reveal the secrets of their underlying mechanisms. With considerable effort over recent years, soft tissue sarcomas have increasingly been classified on the basis of underlying molecular alterations. In turn, this has allowed the development and application of targeted agents in several specific, molecularly defined, sarcoma subtypes. This review will focus on the rationale for targeted therapy in sarcoma, with emphasis on the relevance of specific molecular factors and pathways in both translocation-associated sarcomas and in genetically complex tumors. In addition, we will address some of the early successes in sarcoma-targeted therapy as well as a few challenges and disappointments in this field. Finally, we will discuss several possible opportunities represented by poorly understood, but potentially promising new therapeutic targets, as well as several novel biological agents currently in preclinical and early phase I/II trials. This will provide the reader with the context for understanding the current state of this field and a sense of where it may be headed in the coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.